Icatibant Viatris

Icatibant, the active ingredient in Icatibant Viatris, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in adult patients, providing rapid reduction of swelling and associated discomfort during acute episodes, and is administered by a healthcare professional under medical supervision.

GNH USA supplies Icatibant Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide.

Icatibant is used to treat hereditary angioedema, a disorder characterized by episodic swelling due to excess bradykinin.

Hereditary angioedema type I: rapid relief of swelling and pain during acute attacks Hereditary angioedema type II: rapid relief of swelling and pain during acute attacks Hereditary angioedema with normal C1‑inhibitor: reduces severity and duration of attacks

Icatibant may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain - Redness at injection site - Nausea - Headache

Serious or Rare Side Effects: - Anaphylaxis (severe hypersensitivity reaction) - Airway edema leading to breathing difficulty - Significant hypotension

Before initiating therapy, consider the following precautions.

Monitor for hypersensitivity: observe patient after first injection for signs of allergic reaction. Avoid use in patients with known hypersensitivity to icatibant or its excipients. Use with caution in cardiovascular disease: bradykinin blockade may affect blood pressure. Assess renal function: adjust therapy in severe renal impairment if necessary. Pregnancy and lactation: limited clinical data; prescribe only if benefit outweighs potential risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines; review the following.

Major Interactions (Avoid): - ACE inhibitors: increase bradykinin levels and may exacerbate angioedema. - Angiotensin receptor blockers (ARBs): similar risk of enhanced bradykinin‑mediated edema.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may increase frequency of hereditary angioedema attacks. - Other bradykinin B2 receptor antagonists: additive pharmacologic effect, monitor for excessive blockade. - Immunosuppressive agents: potential increased infection risk, observe patient closely.